Q BioMed Company Executives
| QBIO Stock | USD 0.0001 0.00 0.00% |
Q BioMed employs about 3 people. The company is managed by 6 executives with a total tenure of roughly 7 years, averaging almost 1.0 years of service per executive, having 0.5 employees per reported executive. Analysis of Q BioMed's management performance can provide insight into the firm performance.
| William Rosenstadt Insider G Officer |
| David LaskowPooley Insider VP Devel |
QBIO |
Q BioMed Management Team Effectiveness
The company has return on total asset (ROA) of (5.1182) % which means that it has lost $5.1182 on every $100 spent on assets. This is way below average. Q BioMed's management efficiency ratios could be used to measure how well Q BioMed manages its routine affairs as well as how well it operates its assets and liabilities.Q BioMed Workforce Comparison
Q BioMed is rated below average in number of employees category among its peers. The total workforce of Biotechnology industry is at this time estimated at about 96.0. Q BioMed holds roughly 3.0 in number of employees claiming about 3% of stocks in Biotechnology industry.
Q BioMed Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Q BioMed Price Series Summation is a cross summation of Q BioMed price series and its benchmark/peer.
Q BioMed Notable Stakeholders
A Q BioMed stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Q BioMed often face trade-offs trying to please all of them. Q BioMed's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Q BioMed's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| William Rosenstadt | G Officer | Profile | |
| David LaskowPooley | VP Devel | Profile | |
| Ari Jatwes | Bus Analyst | Profile | |
| Denis Corin | CEO Chairman | Profile | |
| Robert Derham | VP Products | Profile | |
| Amy Ripka | Medicinal Advisor | Profile |
About Q BioMed Management Performance
The success or failure of an entity such as Q BioMed often depends on how effective the management is. Q BioMed management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of QBIO management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the QBIO management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York. Q Biomed operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 3 people.
Q BioMed Workforce Analysis
Traditionally, organizations such as Q BioMed use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Q BioMed within its industry.Q BioMed Manpower Efficiency
Return on Q BioMed Manpower
| Revenue Per Employee | 65.2K | |
| Revenue Per Executive | 32.6K | |
| Net Loss Per Employee | 2.7M | |
| Net Loss Per Executive | 1.4M |
Other Information on Investing in QBIO Pink Sheet
Q BioMed financial ratios help investors to determine whether QBIO Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in QBIO with respect to the benefits of owning Q BioMed security.